EVG Evgen Pharma

EQS-News: Evgen Pharma 'cash runway in pretty good shape'

EQS-News: Evgen Pharma PLC
Evgen Pharma 'cash runway in pretty good shape'

12.12.2022 / 12:53 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive

Proactive UK Ltd

3


News Source: News Direct

12.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Evgen Pharma PLC
United States
ISIN: GB00BSVYN304
EQS News ID: 1510673

 
End of News EQS News Service

1510673  12.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1510673&application_name=news&site_id=research_pool
EN
12/12/2022

Underlying

EVGEvgen Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evgen Pharma

Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf (TCF) | FY25 results: expanded portfolio; focus on Ox-1

TheraCryf has released results for the year to March 2025 with the next 12-18 months set to be pivotal for the company as it focuses on advancing its Orexin-1 (Ox-1) programme while the Sulforaphane (SFX-01) programmes continue with third party funding. During FY25, the company acquired Chronos Therapeutics, making it a multi-compound drug developer, and raised a total of £5.2m, gross, funding the Ox-1 programme through to clinical readiness while extending TheraCryf's cash runway to 4Q 2026. Th...

06/03/25 June 3, 2025 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf (TCF) | Pharmaron contracted to progress Ox-1 programme

Following its £4.25m fund raise last February, TheraCryf has now appointed Pharmaron, a leading contract manufacturing and research organisation (CMD/CRO), to progress development of TheraCryf's Orexin programme for the treatment of addiction to the point at which clinical trials in humans can commence. Pharmaron is expected to commence work imminently with expected completion of all necessary studies in 2H26 leaving TheraCryf on track to start a Phase 1 clinical trial in 2026, subject to fundin...

05/12/25 May 12, 2025 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf (TCF) | £4.3m raise to advance Ox-1 to clinical trial readin...

Further to the Chronos acquisition in 2024, TheraCryf has conditionally raised £4.25m to advance its Orexin programme to clinical trial readiness and now has a cash runway through the end of calendar 2026. The company expects to issue 1.7bn shares at 0.25p/share. While the discount is steep, TheraCryf believes it has the most selective Ox-1 inhibitor molecule in drug development with significant patent protection, targeting a market with multi-billion dollar potential for the treatment of addict...

02/19/25 February 19, 2025 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf |1HFY25 results – Cash guidance confirmed

The first half of FY25 has been a busy one for TheraCryf. The company closed the Chronos acquisition, trebling its pipeline of development assets, and it completed a £0.9m equity raise. The Erasmus University study on SFX-01, the company's lead clinical asset, is making good progress while the granting of a patent covering the company's Orexin-1 molecule by the European Patent Office has just been announced. Despite its advantages, TheraCryf trades on a fraction of the rating of most peers with...

11/28/24 November 28, 2024 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf | R&D Day confirms potential

TheraCryf held a Research and Development Day (R&DD) concentrating on the progress of SFX-01, its lead clinical asset in the study relating to glioblastoma at Erasmus University in the Netherlands, and on the two new candidates acquired in the Chronos acquisition. The Erasmus study is demonstrating very encouraging initial results with the drug on track for trial in humans by early 2026. The R&DD explained the differentiated potential in the Orexin and dopamine transporter (DAT) inhibitor progr...

06/14/24 June 14, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch